Regulatory Watch: France – Moving Transparency from a Stand-alone, “Must-Do” Process to a Tool for Compliance Programs

Over the last six months, France has been a hotspot for compliance-related activity.
On December 9, 2016, France passed a new anti-corruption law, Sapin II, setting expectations for the establishment of robust compliance programs. On December 30, 2016 and March 22, 2017, France augmented transparency reporting requirements for Life Sciences companies with two new decrees.
Last month, Jean-Jacques Mourad, a cardiologist and political advisor to presidential candidate Emmanuel Macron, resigned following accusations that payments he received from the pharmaceutical company Servier represented a conflict of interest. These accusations emerged from analyses conducted on the French public transfers of values database, which demonstrates that French transparency data is being utilized by the public to assess industry relationships with healthcare providers (and especially those with political influence). As in the US, where federal prosecutors are using Open Payments data to support investigations, in France the use of transparency data in investigations will likely happen soon, if it is not already occurring.

To read the article by Caroline Franco

Actually, it already occured: https://market-it.fr/pharmacomplianceinfo/11265/transparency/loi-bertrand/transparence-utilise-autorites-materialiser-infractions-a-loi-anti-cadeaux/

Check Also

loi bertrand, leem, dmos, cahuzac, réforme du médicament, transparence, liens d'intérêts

Réponse du Leem à l’article du Canard Enchaîné publié le 8 novembre 2017 : “Des labos soignant l’éthique”.

FAUX : Non, les nouvelles règles de transparence ne créent pas une plus grande opacité. …